Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 242 results:
Συντάκτης Τίτλος Τύπος [ Έτος![(Asc)](https://www.med.auth.gr/sites/all/modules/biblio/misc/arrow-asc.png)
Φίλτρα: Συντάκτης is Kountouras, Jannis [Clear All Filters]
Association between Infection and Nasal Polyps: A Systematic Review and Meta-Analysis..
Microorganisms. 11(6),
(2023). Autonomic Dysfunction and Somatization in Young Patients With Irritable Bowel Syndrome and Mitral Valve Prolapse Syndrome..
J Neurogastroenterol Motil. 29(3), 403-404.
(2023). Controlling the Impact of -Related Hyperhomocysteinemia on Neurodegeneration..
Medicina (Kaunas). 59(3),
(2023). Impact of nonalcoholic fatty liver disease-related metabolic state on depression..
Neurochem Int. 163, 105484.
(2023). Innate immunity and nonalcoholic fatty liver disease..
Ann Gastroenterol. 36(3), 244-256.
(2023). Letter: higher severe outcomes among Helicobacter pylori-related lean patients with non-alcoholic fatty liver disease and metabolic comorbidities..
Aliment Pharmacol Ther. 57(10), 1186-1187.
(2023). Letter: Histological changes among asymptomatic chronic HBV carriers with normal alanine aminotransferase levels..
Aliment Pharmacol Ther. 58(11-12), 1252-1253.
(2023). Nonalcoholic fatty liver disease and Helicobacter pylori infection. Is it time to address this potential relationship?.
Curr Vasc Pharmacol.
(2023). Nonalcoholic fatty liver disease test: an external validation cohort..
Hormones (Athens).
(2023). Potential impact of Helicobacter pylori infection on hepatic steatosis and metabolic risk factors among patients with chronic hepatitis B..
J Viral Hepat.
(2023). Potential impact of trained innate immunity on the pathophysiology of metabolic dysfunction-associated fatty liver disease..
Clin Immunol. 256, 109776.
(2023). Wnt/beta-catenin signaling inhibitors and nonalcoholic fatty liver disease: Potential therapeutic implications..
Hepatobiliary Pancreat Dis Int.
(2023).
(2022).
Diagnostic approach to -related gastric oncogenesis..
Ann Gastroenterol. 35(4), 333-344.
(2022). Emerging parameters relevant to the management of antimicrobial-resistant Helicobacter pylori infection..
Intern Med J. 52(9), 1654-1655.
(2022). GM-CSF as a potential candidate of a vaccine-induced reduction of Helicobacter pylori infection..
Helicobacter. 27(3), e12884.
(2022). Impact of Active Helicobacter pylori Infection-related Metabolic Syndrome on Systemic Arterial Hypertension..
Arq Bras Cardiol. 119(3), 502-504.
(2022). Letter to the Editor Regarding "The Association of Helicobacter pylori, Eradication, and Early Complications of Laparoscopic Sleeve Gastrectomy" by Abeid et al..
Obes Surg. 32(6), 2079-2080.
(2022). Potential impact of Helicobacter pylori and metabolic syndrome-related non-alcoholic fatty liver disease on cardio-cerebrovascular disease..
Metabolism. 135, 155276.
(2022). Potential Impact of Helicobacter pylori Infection on Pancreatic Cancer Pathophysiology..
J Gastrointest Cancer.
(2022). A potential impact of Helicobacter pylori-related metabolic syndrome on early and long-term outcomes of bariatric surgery..
Gastrointest Endosc. 96(6), 1088-1089.
(2022).
(2022). Cilofexor for the Treatment of Nonalcoholic Steatohepatitis.
Curr Vasc Pharmacol.
(2021). Effect of spironolactone on pharmacological treatment of nonalcoholic fatty liver disease..
Minerva Endocrinol (Torino).
(2021). Helicobacter pylori infection and diabetes mellitus..
Diabetes Metab Syndr. 15(3), 845-846.
(2021).